Analysis of the current literature showed that many genes over-expressed in primary and metastatic prostate cancer are regulated by Sp TFs and are potential targets of the MTM-A analogues (see Methods S1, Table S1, S2 and references therein). The gene discussed is TFF2; the disease is prostate carcinoma.